Tesa IPA CJC Blend: What It Is and How It Works

A tesa IPA CJC blend is a single research vial that combines tesamorelin, ipamorelin, and CJC-1295 in a fixed ratio. All three are growth hormone secretagogues, meaning they prompt the pituitary to release more growth hormone, but each one binds a different receptor and stays active for a different length of time. Only tesamorelin is FDA-approved in the United States, and only for a narrow medical indication; CJC-1295 and ipamorelin are unapproved research chemicals.

What Each Peptide in the Blend Does

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. It binds GHRH receptors in the pituitary, and it is the only component of the blend backed by large clinical trials.

Ipamorelin is a selective ghrelin receptor agonist. It was designed to trigger GH release with less hunger and cortisol impact than older ghrelin mimetics, which is part of why it appears in so many stacks.

CJC-1295 is also a GHRH analog, and it comes in two forms. CJC-1295 with DAC uses a Drug Affinity Complex that binds albumin and extends its half-life to roughly a week, while CJC-1295 without DAC (mod GRF 1-29) clears in about half an hour.

Peptide	Receptor target	Approximate half-life	US regulatory status
Tesamorelin	GHRH receptor	26 to 38 minutes (subcutaneous)	FDA-approved (Egrifta WR) for HIV-associated visceral adiposity
Ipamorelin	Ghrelin receptor (GHS-R1a)	About 2 hours	Not approved for human use
CJC-1295 with DAC	GHRH receptor	6 to 8 days	Not approved for human use
CJC-1295 without DAC	GHRH receptor	About 30 minutes	Not approved for human use

Common Blend Ratios and What They Mean

Vendors print the ratio on the label, usually as three numbers representing tesamorelin, ipamorelin, and CJC-1295. The ratio tells you how the manufacturer weighted each peptide, not how the blend behaves in a living system.

Because the three peptides clear at very different speeds, a fixed-ratio vial can only approximate the release pattern you would get from three separate vials. That is one reason experienced researchers often prefer to control each peptide independently.

Labeled ratio (tesa:ipa:CJC)	What it emphasizes	Practical note
1:1:1	Equal parts of all three	Most common blend configuration
2:1:1	Tesamorelin-forward	More GHRH-receptor activity per milligram
1:2:1	Ipamorelin-forward	Shorter, more frequent pulses
1:1:2	CJC-heavy	Usually paired with the no-DAC form

Tesa/Ipa/CJC vs. Other Growth Hormone Peptide Options

Anyone weighing a three-peptide blend against simpler options tends to compare the same variables: receptor targets, injection frequency, and how much human data exists.

A straight cjc-1295 ipamorelin vs tesamorelin comparison is the most common starting point. Tesamorelin wins on evidence, since it completed Phase 3 trials and holds an approval. The CJC-1295 side wins on convenience, because the DAC form needs far fewer injections.

Option	Targets	Typical research frequency	Evidence base
Tesamorelin alone	GHRH receptor	Once daily	Strongest; FDA approval and Phase 3 data
CJC-1295 plus ipamorelin	GHRH and ghrelin receptors	1 to 3 times daily	Small, short-term human studies
Tesa IPA CJC blend	GHRH and ghrelin receptors	Once or twice daily	No published trials on the blend itself
Ipamorelin alone	Ghrelin receptor	2 to 3 times daily	Mostly animal and small human data
Sermorelin	GHRH receptor	Once daily	Older; previously approved, later withdrawn

Timing, Formats, and Research Practicalities

Growth hormone release is pulsatile and peaks during deep sleep, so the best time to take cjc 1295 ipamorelin in most published protocols is at night or in a fasted state, when insulin and free fatty acids are less likely to blunt the pulse.

Blends follow the same logic. A single evening administration is the most common pattern, though some protocols split the total amount into two smaller doses to mimic a more natural rhythm.

So, does cjc-1295 work? Short human studies show that GHRH analogs and ghrelin mimetics reliably raise GH and IGF-1 levels on lab tests. What those studies do not show is a proven long-term benefit for body composition, recovery, or healthy aging.

Format matters too. Nearly all research uses subcutaneous injection, and cjc 1295 capsules face the same obstacle as any oral peptide: stomach acid and poor absorption. Oral versions are widely sold but thinly supported by data.

Claims about muscle growth from these peptides usually trace back to IGF-1 signaling rather than to direct muscle studies. No large trial has confirmed those claims in healthy adults.

Safety, Sourcing, and Legal Status

Tesamorelin is approved in the US as Egrifta WR for excess visceral fat in adults with HIV and lipodystrophy. CJC-1295 and ipamorelin have no approved human use, and blends sold online are unregulated research chemicals.

Reported side effects of growth hormone stimulation include fluid retention, joint aches, numbness or tingling in the hands, injection site reactions, and elevated blood sugar. Anyone with a history of diabetes, cancer, or pituitary conditions should talk with a healthcare professional before considering these compounds.

Sourcing is a genuine risk. Because blends are unregulated, the labeled ratio may not match the vial contents, and independent third-party testing is not guaranteed. Threads such as tesa/ipa blend reddit discussions are anecdotal and cannot verify purity or identity.

None of this is medical advice, and these peptides are not a substitute for a diagnosis or a prescription from a licensed clinician.

Bottom Line

A tesa IPA CJC blend packages three GH secretagogues into one vial for convenience, not for proven synergy. Tesamorelin carries the strongest evidence and the only FDA approval, while CJC-1295 and ipamorelin remain experimental.

If you are comparing blends, ask what the ratio actually accomplishes given the very different half-lives, and treat marketing claims with the same skepticism you would apply to any unapproved product.

COMMON QUESTIONS

Frequently Asked Questions

What is a tesa IPA CJC blend?

It is a combined research peptide vial containing tesamorelin, ipamorelin, and CJC-1295 in a fixed milligram ratio. All three stimulate growth hormone release, but they act on different receptors and have very different half-lives. Blends are sold as unregulated research chemicals.

Is a tesa IPA CJC blend legal in the United States?

Tesamorelin itself is FDA-approved as Egrifta WR for a narrow indication involving HIV-associated visceral fat. CJC-1295 and ipamorelin are not approved for human use, so blends containing them are sold only for laboratory research. Buying them for personal use is not legal and carries real sourcing risks.

Does a tesa IPA CJC blend raise growth hormone?

Short-term human studies show that GHRH analogs and ghrelin mimetics reliably increase measured GH and IGF-1 levels. That does not mean the blend produces proven long-term benefits for fat loss, muscle, or recovery. No published trials have tested the three-peptide blend as a combination.